SUMMARY Ceftriaxone, a third generation cephalosporin, was used in a single intramuscular dose with oral probenecid to treat 124 men with infections due to non-penicillinase-producing Neisseria gonorrhoeae (non-PPNG) and 64 men with infections due to PPNG. Three different doses of ceftriaxone were used-125 mg, 62S5 mg, and 32S5 mg. The cure rate for all PPNG infections with the different doses was 10007. The cure rate for the non-PPNG infections with ceftriaxone 125 mg was OOWo; those for non-PPNG infections treated with ceftriaxone 62S5 mg and 32S5 mg were 96' 207o and 97' 3 Oo respectively. The 160 strains of non-PPNG and 60 strains of PPNG isolated were all susceptible to ceftriaxone with minimum inhibitory concentrations of 0'008 ,ug/ml. These results are compared with those using kanamycin 2 g. Ceftriaxone is a safe and effective treatment for PPNG and non-PPNG infections.
Introduction
The first cephalosporin was isolated in 1955 and since then different generations, each showing advantages over the previous one, have been produced. The newer generations show increasing activity, a broader antimicrobial spectrum, and increased stability to penicillinase.
When compared with other cephalosporins of the same class1 2 ceftriaxone, a new third generation cephalosporin, has been found to be highly active against strains of both penicillinase-producing Neisseria gonorrhoeae (PPNG) and non-penicillinaseproducing N gonorrhoeae (non-PPNG). Ceftriaxone is an aminothiazolyl-oxyimino-cephalosporin, which is different from other cephalosporins in the nature of the substitution at position 3 of the nucleus (figure). The presence of an enolate axion group at the triazine moiety of the 3-substituent probably contributes to its long plasma half-life.
The bioavailability of ceftriaxone when dissolved 
Results
The details of the treatment response are given in table I. There were no treatment failures in all three groups of patients infected with PPNG when treated either with ceftriaxone with probenecid or with kanamycin. The overall failure rate with kanamycin in the patients infected with non-PPNG strains was 11%.
POSTGONOCOCCAL URETHRITIS
There was no significant difference in the incidence of postgonococcal urethritis in patients treated with kanamycin or with ceftriaxone. The overall incidence of postgonococcal urethritis in patients treated either 
